Overview
- 76 inspections across 72 sites are on record.
- 14 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-22.
At a glance
Inspections
76
Sites
72
Observations
14
Career since
Jan 2019
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| ICON PLC | 22 May 2026 | Human Drugs | |
| ICON PLC | 20 May 2026 | Human Drugs | |
| Amy T. Waldman, MD, MSCE | 24 Apr 2026 | Human Drugs | |
| Cameron Olezene, M.D. | 1 Apr 2026 | Human Drugs | View 483 → |
| Qiagen Manchester Ltd. | 24 Feb 2026 | Medical Devices & Rad Health |
Sites inspected
ICON PLCBlue Bell, United States2 insp.
Amy T. Waldman, MD, MSCEPhiladelphia, United States1 insp.
Cameron Olezene, M.D.Plymouth Meeting, United States1 insp.
Qiagen Manchester Ltd.Manchester, United Kingdom1 insp.
Co-investigators
Investigators who share inspections with this person.
Anastasia I Offordile11 shared
Gabrielle J Swain6 shared
Christopher Bastedo3 shared
Sam Pepe2 shared
Stephanie C Mangigian2 shared
Kelly N Kerr1 shared
Byungja E Marciante1 shared
Joseph L Despins1 shared
Full investigator report
Get the verbatim findings behind Anastasia I Onuorah's 14 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site